Related Experiment Videos
[Intraperitoneal hyperthermic chemotherapy. Preliminary experience with 22 consecutive patients].
V Ceriani1, P Bignami, E Faleschini
1UO Chirurgia Generale, Policlinico Polispecialisticio MultiMedica, Sesto San Giovanni (Mi).
Summary
This study evaluated surgical treatment and intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. The combined approach showed promising survival rates with manageable complications in patients with advanced cancer.
Area of Science:
- Oncology
- Surgical Oncology
- Chemotherapy
Context:
- Peritoneal carcinomatosis presents a significant challenge in cancer treatment.
- Evaluating multimodal treatment strategies is crucial for improving patient outcomes.
- Intraperitoneal hyperthermic chemotherapy (IPHC) is an advanced treatment modality.
Purpose:
- To assess the efficacy and safety of surgical treatment combined with intraperitoneal hyperthermic chemotherapy.
- To analyze complication rates and survival data in patients with peritoneal carcinomatosis.
- To report on the outcomes of IPHC in a clinical setting.
Summary:
- The study included 22 patients with peritoneal carcinomatosis treated between 2001 and 2004.
- Surgical complications occurred in 23% of patients, with a 13% post-operative mortality rate.
- No chemotherapy-related toxicity was observed, and survival ranged from 4 to 40 months post-operation.
Impact:
- This research contributes to understanding the role of IPHC in managing advanced cancers.
- The findings suggest IPHC can be a viable option with acceptable toxicity profiles.
- Further research may optimize IPHC protocols for improved oncological results.